[go: up one dir, main page]

BR9711843A - Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos - Google Patents

Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos

Info

Publication number
BR9711843A
BR9711843A BR9711843-5A BR9711843A BR9711843A BR 9711843 A BR9711843 A BR 9711843A BR 9711843 A BR9711843 A BR 9711843A BR 9711843 A BR9711843 A BR 9711843A
Authority
BR
Brazil
Prior art keywords
mupirocin
nasopharynx
colonization
medicine
manufacture
Prior art date
Application number
BR9711843-5A
Other languages
English (en)
Inventor
Timothy John Henkel
Anthony Guy Hatton
Teresita Regina Geradin Tallon
Hugh Scott
Jane Elizabeth Hilton
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9716805.8A external-priority patent/GB9716805D0/en
Priority claimed from GBGB9719203.3A external-priority patent/GB9719203D0/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of BR9711843A publication Critical patent/BR9711843A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE MUPIROCINA PARA A FABRICAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE INFECçõES BACTERIANAS ASSOCIADAS COM COLONIZAçãO DA NASOFARINGE POR ORGANISMOS PATOGêNICOS Mupirocina ou um seu sal ou éster pode ser usado para tratar sinusite recorrente e otite recorrente, em particular com novas formulações borrifáveis e cremosas adaptadas para administração à nasofaringe.
BR9711843-5A 1996-10-01 1997-09-29 Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos BR9711843A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2722396P 1996-10-01 1996-10-01
US2722496P 1996-10-01 1996-10-01
US2722296P 1996-10-01 1996-10-01
GBGB9716805.8A GB9716805D0 (en) 1997-08-09 1997-08-09 Novel composition and use
GBGB9719203.3A GB9719203D0 (en) 1997-09-11 1997-09-11 Novel composition and use
PCT/GB1997/002664 WO1998014189A1 (en) 1996-10-01 1997-09-29 Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms

Publications (1)

Publication Number Publication Date
BR9711843A true BR9711843A (pt) 2001-07-31

Family

ID=27517419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711843-5A BR9711843A (pt) 1996-10-01 1997-09-29 Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos

Country Status (17)

Country Link
US (1) US6001870A (pt)
EP (1) EP0939631A1 (pt)
JP (1) JP2001504091A (pt)
KR (1) KR20000048812A (pt)
CN (1) CN1239427A (pt)
AR (1) AR010995A1 (pt)
AU (1) AU724070B2 (pt)
BR (1) BR9711843A (pt)
CA (1) CA2267248A1 (pt)
CZ (1) CZ112499A3 (pt)
HU (1) HUP9904308A3 (pt)
IL (1) IL129237A0 (pt)
NO (1) NO991548L (pt)
NZ (1) NZ334913A (pt)
PL (1) PL332642A1 (pt)
TR (1) TR199900733T2 (pt)
WO (1) WO1998014189A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4910145A1 (es) * 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
NZ334913A (en) * 1996-10-01 2001-03-30 Smithkline Beecham Plc Use of mupirocin (pseudomonic acid) for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms effective as a sprayable topical agent
EP1001747A1 (en) * 1997-08-09 2000-05-24 Smithkline Beecham Plc Compositions for nasal administration
UY25225A1 (es) 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9902138D0 (en) 1999-02-02 1999-03-24 Smithkline Beecham Container
HRP20010576A2 (en) * 1999-02-03 2002-08-31 Biogal Gyogyszergyar Process for the preparation of pseudomonic acid a antibiotic by microbiological method
EP1185246A1 (de) * 1999-06-02 2002-03-13 Klöcker, Norbert, Dr.med. Pharmazeutische zusammmensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslischen wirkstoffen
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
HUP0500797A2 (en) * 2001-06-21 2007-06-28 Biogal Gyogyszergyar Metabolic controlled fermentation process for pseudomonic acid production
EP1455769A4 (en) 2001-12-28 2004-09-22 Biogal Gyogyszergyar METHOD FOR PRODUCING CRYSTALLINE AND AMORPHIC MUPIROCIN CALCIUM
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
DK1641438T3 (da) * 2004-06-01 2010-06-07 Teva Gyogyszergyar Zartkoeruen Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel
CN101175474B (zh) 2005-03-10 2011-09-07 3M创新有限公司 降低微生物污染的方法
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
CA2599667C (en) 2005-03-10 2014-12-16 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxy carboxylic acids
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
ES2759373T3 (es) 2008-06-12 2020-05-08 Medtronic Xomed Inc Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
US20100021563A1 (en) * 2008-07-24 2010-01-28 Paul Levesque Compositions comprising coconut oil and methods of use thereof
US20100086576A1 (en) 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
JP6463629B2 (ja) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ 抗菌性固体およびその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ200918A (en) * 1981-07-02 1985-07-31 Gist Brocades Nv Stable fatty oil-in-water emulsion cream for topical application
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
GB8530796D0 (en) * 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
US5594026A (en) * 1990-12-11 1997-01-14 Smithkline Beecham Group P.L.C. Polymorphs of crystalline mupirocin
WO1995010999A1 (en) * 1993-10-22 1995-04-27 Smithkline Beecham Corporation Novel composition
NZ334913A (en) * 1996-10-01 2001-03-30 Smithkline Beecham Plc Use of mupirocin (pseudomonic acid) for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms effective as a sprayable topical agent

Also Published As

Publication number Publication date
NZ334913A (en) 2001-03-30
AU4562397A (en) 1998-04-24
HUP9904308A3 (en) 2002-06-28
NO991548L (no) 1999-03-31
AR010995A1 (es) 2000-08-02
AU724070B2 (en) 2000-09-14
US6001870A (en) 1999-12-14
EP0939631A1 (en) 1999-09-08
CZ112499A3 (cs) 1999-08-11
IL129237A0 (en) 2000-02-17
CN1239427A (zh) 1999-12-22
WO1998014189A1 (en) 1998-04-09
HUP9904308A2 (hu) 2001-04-28
PL332642A1 (en) 1999-09-27
KR20000048812A (ko) 2000-07-25
CA2267248A1 (en) 1998-04-09
JP2001504091A (ja) 2001-03-27
TR199900733T2 (xx) 1999-07-21
NO991548D0 (no) 1999-03-30

Similar Documents

Publication Publication Date Title
BR9711843A (pt) Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos
PT759774E (pt) Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
David et al. Bacterial infection and atopic eczema.
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
PT754050E (pt) Metodos e materiais contra bacterias gram-positivas
DE60020351D1 (de) Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
BR0214583A (pt) Formulações compreendendo um composto de cefalosporina e seus usos no tratamento de infecções bacterianas em gatos e cães
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
MY120501A (en) Micro-encapsulated lactobacilli for medical applications
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR9811535A (pt) Composições farmacêuticas contendo lisostafina sozinha ou em combinação com um antibiótico para o tratamento de infecções por estafilocócico
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
Isenberg et al. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with β-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia
PT90592A (pt) Processo para a preparacao do antibiotico galidermina e de composicoes farmaceuticas e cosmeticas que o contem
Kiefer et al. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme
Acar et al. Use of rifampin for the treatment of serious staphylococcal and gram-negative bacillary infections
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BR0100228A (pt) Macrolìdeos com 13 e 14 elementos antibacterianos e procinéticos e seus intermediários
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
Neu et al. The inhibitory quotient
Hewitt Treatment of urinary tract infections with streptomycin
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
Ghalaut et al. Piperacillin–Tazobactum Plus Amikacin Versus Ceftazidime Plus Amikacin as Empirical Therapy for Fever in Neutropenic Patients with Hematological Malignancies

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1835 DE 07/03/2006.